EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Effectiveness, safety, and biomarker analysis of lenvatinib plus toripalimab as chemo-free therapy in advanced intrahepatic cholangiocarcinoma: a real-world study

Shanshan Wang, Jiashuo Chao, Hao Wang, Shuofeng Li, Yunchao Wang, Chengpei Zhu, Nan Zhang, Mingjian Piao, Xu Yang, Kai Liu, Ziyu Xun, Xinting Sang und 3 weitere

Cancer Immunology, Immunotherapy · 03.10.2024 · 73 (12)

DOI: 10.1007/s00262-024-03841-z ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 03.10.2024. Verfasst von Shanshan Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Complex Severe and Rare Diseases, Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medi…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Quinolines, Phenylurea Compounds, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CAMS Innovation Fund for Medical Sciences(CIFMS), CSCO-hengrui Cancer Research Fund, National High Level Hospital Clinical Research Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Treatment options for advanced intrahepatic cholangiocarcinoma (ICC) are currently limited. Chemo-containing regimens are the mainstay treatments but associated with notable toxicity, poor tolerance, and reduced compliance, necessitating exploration of alternative therapies. Lenvatinib plus PD-1 inhibitors has shown substantial clinical activity in preliminary studies. This study aimed to assess the effectiveness and safety of lenvatinib plus toripalimab (a novel PD-1 antibody) as chemo-free therapy in advanced ICC. METHODS: This retrospective study included consecutive advanced ICC patients receiving lenvatinib plus toripalimab between February 2019 and December 2023. The main outcomes were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and safety. Prognostic factors and exploratory analyses for genetic alternations were also conducted. RESULTS: A total of 78 patients were included, with a median follow-up of 25.9 months. Median OS and PFS were 11.3 (95% CI: 9.5-13.1) and 5.4 (95% CI: 3.8-7.0) months, respectively. ORR was 19.2% and DCR was 75.6%. The incidence of grade 3 or 4 adverse events (AEs) was 50.0%, with no grade 5 AEs reported. Patients with normal baseline CA19-9 levels exhibited a higher ORR (p = 0.011), longer PFS (11.5 versus 4.6 months; HR 0.47; p=0.005), and OS (21.0 versus 9.7 months; HR 0.43; p=0.003). The presence of IDH1 mutations correlated with increased ORR (60.0% versus 8.9%, p=0.016). CONCLUSION: Lenvatinib plus toripalimab represents an effective and well-tolerated chemo-free therapeutic option for advanced ICC. Baseline CA19-9 levels and IDH1 mutations may serve as predictive treatment-related biomarkers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaQuinolinesPhenylurea CompoundsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBile Duct NeoplasmsHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAdultPrognosisAged, 80 and over

Stichwörter der Autor:innen

CA19-9CholangiocarcinomaIDH1LenvatinibPD-1 inhibitorPD-L1

Substanzen

lenvatinibQuinolinesPhenylurea CompoundsAntibodies, Monoclonal, HumanizedBiomarkers, Tumortoripalimab

Autor:innen und Institutionen

  • State Key Laboratory of Complex Severe and Rare Diseases, Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing,…
  • Organ Transplantation Center, The First Affiliated Hospital of Shandong First Medical University, Jinan, China.
  • Department of General Surgery Center, Beijing Youan Hospital, Clinical Center for Liver Cancer, Capital Medical University, Beijing, China.
  • Faculty of Hepato-Pancreato-Biliary Surgery, Chinese PLA General Hospital, No. 28, Fuxing Road, Haidian District, Beijing, China. duanwd301@163.com.

Förderung

  • CAMS Innovation Fund for Medical Sciences(CIFMS)
  • CSCO-hengrui Cancer Research Fund
  • National High Level Hospital Clinical Research Funding
  • CSCO-MSD Cancer Re-search Fund
  • National Ten-thousand Talent Program

Zitieren

APA

Wang, S., Chao, J., Wang, H., Li, S., Wang, Y., Zhu, C., Zhang, N., Piao, M., Yang, X., Liu, K., Xun, Z., Sang, X., Yang, X., Duan, W., & Zhao, H. (2024). Effectiveness, safety, and biomarker analysis of lenvatinib plus toripalimab as chemo-free therapy in advanced intrahepatic cholangiocarcinoma: a real-world study. Cancer Immunology, Immunotherapy, 73(12). https://doi.org/10.1007/s00262-024-03841-z

Vancouver

Wang S, Chao J, Wang H, Li S, Wang Y, Zhu C, et al. Effectiveness, safety, and biomarker analysis of lenvatinib plus toripalimab as chemo-free therapy in advanced intrahepatic cholangiocarcinoma: a real-world study. Cancer Immunology, Immunotherapy. 2024;73(12). doi:10.1007/s00262-024-03841-z

BibTeX
@article{Wang2024,
  author = {Wang, Shanshan and Chao, Jiashuo and Wang, Hao and Li, Shuofeng and Wang, Yunchao and Zhu, Chengpei and Zhang, Nan and Piao, Mingjian and Yang, Xu and Liu, Kai and Xun, Ziyu and Sang, Xinting and Yang, Xiaobo and Duan, Weidong and Zhao, Haitao},
  title = {Effectiveness, safety, and biomarker analysis of lenvatinib plus toripalimab as chemo-free therapy in advanced intrahepatic cholangiocarcinoma: a real-world study},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  volume = {73},
  number = {12},
  doi = {10.1007/s00262-024-03841-z}
}
Kostenlos starten →